Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA209258
Max Phase: Preclinical
Molecular Formula: C49H77N7O11
Molecular Weight: 940.19
Molecule Type: Small molecule
Associated Items:
ID: ALA209258
Max Phase: Preclinical
Molecular Formula: C49H77N7O11
Molecular Weight: 940.19
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)O
Standard InChI: InChI=1S/C49H77N7O11/c1-6-7-8-9-10-11-12-13-17-23-40(60)54-42(32(4)57)48(65)55-41(31(2)3)46(63)56-43(33(5)58)47(64)52-38(29-35-24-26-36(59)27-25-35)45(62)51-37(22-18-19-28-50)44(61)53-39(49(66)67)30-34-20-15-14-16-21-34/h14-16,20-21,24-27,31-33,37-39,41-43,57-59H,6-13,17-19,22-23,28-30,50H2,1-5H3,(H,51,62)(H,52,64)(H,53,61)(H,54,60)(H,55,65)(H,56,63)(H,66,67)/t32-,33-,37+,38+,39+,41+,42+,43+/m1/s1
Standard InChI Key: SKPCWOADTGRUOD-QNDRFUSQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 940.19 | Molecular Weight (Monoisotopic): 939.5681 | AlogP: 2.64 | #Rotatable Bonds: 33 |
Polar Surface Area: 298.61 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.70 | CX Basic pKa: 17.64 | CX LogP: 1.50 | CX LogD: 1.50 |
Aromatic Rings: 2 | Heavy Atoms: 67 | QED Weighted: 0.05 | Np Likeness Score: 0.23 |
1. Basse N, Papapostolou D, Pagano M, Reboud-Ravaux M, Bernard E, Felten AS, Vanderesse R.. (2006) Development of lipopeptides for inhibiting 20S proteasomes., 16 (12): [PMID:16630721] [10.1016/j.bmcl.2006.03.033] |
Source(1):